Full-Time

Administrator 3

System & Applications Administration

Updated on 7/22/2026

Cencora

Cencora

10,001+ employees

Global pharmaceutical distribution and services provider

No salary listed

Pune, Maharashtra, India

In Person

On-site in Pune with a 24x7 rotating shift schedule.

Category
DevOps & Infrastructure (1)
Required Skills
ServiceNow
SQL
Oracle

Get referred to Cencora

Find people who can refer or advise you

Requirements
  • 4+ years of experience in B2B integration, implementation, and support experience utilizing EDI products.
  • Strong experience with IBM Sterling Integrator or Axway B2B Interchange.
  • Prior experience using Axway to support data exchange is preferred.
  • Experience with handling most EDI formats is a must, including ANSI X12 and EDIFACT.
  • Knowledge and experience troubleshooting SAP IDOC data-related issues.
  • Experience in developing, implementing, and supporting business flows within EDI.
  • Bachelor’s Degree in Computer Science, Information Technology or any other related discipline or equivalent related experience.
  • Understanding of ANSI X12 EDI standards and knowledge of EDI Integration.
  • Understanding production support, support structure, ticketing tools like ServiceNow, shared mailbox support, SLAs.
  • Understanding inter-connection of applications (Enterprise Application integration) in a production environment.
  • Experience in analyzing, reporting transaction failures, file delivery failure Issues.
  • Good communication, reasoning, and analytical skills.
  • Understanding of EDI transactions, ITX mapping knowledge, B2B Integration, business process analysis/development.
  • Knowledge of IBM Sterling B2B Integrator Dashboard and different sections inside the tool to handle Production Support scenarios.
  • Experience with Axway B2BI, Lightwell B2B Framework.
  • Experience with Oracle database.
  • Experience with SQL Developer.
Responsibilities
  • Provide production support, analyze, and resolve common production errors caused by routing issues, translation errors, data discrepancies, connectivity failures, and configuration issues.
  • Work closely with business users and partners for the resolution of production issues.
  • Monitor transactional activity within the Cencora multi-platform/multi-environment EDI system.
  • Work with service providers to ensure business-critical EDI transactions are received, sent, and delivered, and SLAs are met.
  • Use standardized tools, SOPs, and rule sets to ensure service delivery, provide optimal communications, and record analytical information needed for the continuous improvement cycle.
  • Develop and optimize business processes in support of partner onboarding and other EDI organizational tools.
  • Support other Cencora EDI teams with both day-to-day issues and project activities.
Desired Qualifications
  • Salesforce Certified Administrator
  • Microsoft Certified Systems Administrator (MCSA)
  • Microsoft Certified IT Professional
  • ITIL, ITSM Certifications

Cencora provides global pharmaceutical distribution and a range of services, including specialty pharmacy, consulting, supply-chain management, patient support programs, and data analytics for healthcare providers, manufacturers, and veterinary practices. It works by combining physical drug distribution with value-added services such as inventory management, regulatory compliance guidance, patient support, and data-driven insights to optimize supply chains and outcomes. The company differentiates itself with an integrated, end-to-end offering that spans distribution, clinical services, analytics, and advisory support to help clients run more efficient operations and lower costs. Its goal is to improve healthcare outcomes by delivering comprehensive pharmaceutical solutions that enable better care and lower overall expenses.

Company Size

10,001+

Company Stage

IPO

Headquarters

Pennsylvania

Founded

1907

Get referred to Cencora

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • OneOncology acquisition strengthens high-value specialty pharmaceutical positioning
  • New CFO Eva Boratto targets $300M savings using past Bath & Body Works expertise
  • International segment expects 8%-10% revenue growth in 2026 despite FX volatility

What critics are saying

  • Fraud investigation by Frank R. Cruz over May 6 Q2 $2.68B revenue miss risks lawsuits
  • Biosimilar conversions and IRA price cuts slashed revenue growth to 4%-6% from 7%-9%
  • Debt inadequately covered by operating cash flow limits flexibility amid US healthcare slowdown

What makes Cencora unique

  • Leads global pharma distribution with $300B+ revenue and Fortune 500 rank #10
  • Integrates specialty pharmacy, data analytics, and supply chain solutions uniquely
  • Pioneers Nucleus inventory tech for 20+ specialty practices with real-time tracking

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Parental Leave

Adoption Assistance

Infertility Coverage

Family Planning Benefits

Behavioral Health Solutions

Professional Development Budget

Training Programs

Company News

Yahoo Finance
Mar 23rd, 2026
Cencora buys EyeSouth Partners' retina business for $1.1B to expand Retina Consultants of America

Cencora has signed a definitive agreement to acquire EyeSouth Partners' retina business for $1.1 billion. The affiliated retina physicians will join Cencora's Retina Consultants of America, a leading management services organisation. The pharmaceutical solutions company expects the acquisition to be slightly accretive to its adjusted diluted earnings per share in the first twelve months following closure, net of financing costs. The transaction requires regulatory approvals and customary closing conditions. Cencora's reaffirmed fiscal 2026 financial guidance does not currently include the transaction closing within that fiscal year. BofA Securities served as lead financial advisor to Cencora, whilst Jefferies advised EyeSouth Partners, a portfolio company of Olympus Partners.

The Associated Press
Mar 17th, 2026
Cencora CFO James Cleary to retire after eight years, search underway for successor

Cencora has announced that Chief Financial Officer James F. Cleary will retire effective 30 June 2026. The pharmaceutical solutions company has engaged an executive search firm to identify potential successors from internal and external candidates. Cleary, 62, has served as CFO since November 2018 and joined Cencora in February 2015 following its acquisition of MWI Veterinary Supply, where he had been chief executive officer for over a decade. He will serve in an advisory capacity through the end of 2026 to ensure a smooth transition. Cencora reaffirmed its previously issued adjusted diluted earnings per share guidance range of $17.45 to $17.75 for fiscal year 2026. The company, ranked number 10 on the Fortune 500, generates more than $300 billion in annual revenue.

TradingView
Feb 11th, 2026
Cencora prices $3B senior notes offering across multiple maturities

Cencora has priced a $3 billion senior notes offering across various maturities, the company announced on 10 February 2026. No further details about the specific maturities, interest rates or intended use of proceeds were disclosed in the announcement.

Yahoo Finance
Feb 4th, 2026
Cencora raises fiscal 2026 guidance after completing OneOncology acquisition

Cencora reported 12% adjusted operating income growth and 9% adjusted diluted EPS growth in its fiscal 2026 first quarter, driven by its US healthcare solutions business. The company raised its full-year guidance to reflect year-over-year adjusted operating income growth of 11.5% to 13.5%. CEO Robert Mauch announced the completion of Cencora's acquisition of the majority remaining equity interest in OneOncology. The deal strengthens Cencora's specialty pharmaceutical leadership and MSO (management services organisation) platform. Cencora's strategy focuses on three priorities: strengthening leadership in specialty pharmaceuticals, partnering with market leaders, and enhancing patient access to pharmaceuticals. The company is leveraging technology and advanced analytics to improve customer experience and operational excellence whilst expanding its pharmaceutical-centric MSO footprint.

Yahoo Finance
Feb 4th, 2026
Cencora beats profit estimates on specialty drug demand, completes $5B OneOncology acquisition

Cencora beat Wall Street's first-quarter profit estimates on Wednesday, driven by sustained demand for specialty medicines and GLP-1 therapies. The drug distributor reported adjusted earnings of $4.08 per share, exceeding analysts' expectations of $4.04. The company completed its $5 billion acquisition of OneOncology from TPG in December, strengthening its presence in cancer care. It raised its fiscal 2026 adjusted operating income growth forecast to 11.5% to 13.5%, up from 8% to 10% previously. However, quarterly revenue of $85.93 billion fell short of expectations of $86.03 billion, sending shares down 5% in pre-market trading. Sales at its largest unit, US healthcare solutions, rose 5% year-over-year to $76.2 billion, boosted by prescription volumes of weight-loss drugs and specialty medicines.